Double Autologous Stem Cell Transplantation for Multiple Myeloma: A Korean Single Center Study
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background : Although high dose chemotherapy coupled with an autologous stem cell transplantation (ASCT) is widely accepted as effective therapy for multiple myeloma (MM), few reports are available in Korea, especially in the area of double ASCT. We present the results of an institutional retrospective study of 12 patients with MM treated by double ASCT. Methods : Eligible patients received induction therapy using vincristine, adriamycin, dexamethasone (VAD), and mobilization was performed using cyclophosphamide plus lenograstim. High-dose melphalan (total 200 mg/m2) was used to condition the ASCT. Results : The median interval from diagnosis to ASCT was 6 months (range, 1.8-15.3 months). The median interval between the 1st and 2nd ASCT was 4.4 months (range 2.1-48.7 months). The median follow up was 18.3 months (range 8.1-50.5 months) for the nine surviving patients. No therapy-related mortality occurred. Following induction chemotherapy, two patients experienced CR. Following double ASCT, eight patients experienced CR. The 5 year OS was 59%. The median duration of event free survival was 2.13 years (95% CI, 0.84-3.42). Conclusion : Although the results of study did not demonstrate the advantage of double ASCT, this is the first report to outline the outcome of double ASCT for Korean MM patients.
Abstract
Background : Although high dose chemotherapy coupled with an autologous stem cell transplantation (ASCT) is widely accepted as effective therapy for multiple myeloma (MM), few reports are available in Korea, especially in the area of double ASCT. We present the results of an institutional retrospective study of 12 patients with MM treated by double ASCT. Methods : Eligible patients received induction therapy using vincristine, adriamycin, dexamethasone (VAD), and mobilization was performed using cyclophosphamide plus lenograstim. High-dose melphalan (total 200 mg/m2) was used to condition the ASCT. Results : The median interval from diagnosis to ASCT was 6 months (range, 1.8-15.3 months). The median interval between the 1st and 2nd ASCT was 4.4 months (range 2.1-48.7 months). The median follow up was 18.3 months (range 8.1-50.5 months) for the nine surviving patients. No therapy-related mortality occurred. Following induction chemotherapy, two patients experienced CR. Following double ASCT, eight patients experienced CR. The 5 year OS was 59%. The median duration of event free survival was 2.13 years (95% CI, 0.84-3.42). Conclusion : Although the results of study did not demonstrate the advantage of double ASCT, this is the first report to outline the outcome of double ASCT for Korean MM patients.
참고문헌 (25)
- "Central Cancer Registry Center and Ministry of Health and Welfare" (1999), Annual report of the central registry in Korea
- "A statistical study of multiple myeloma in Korea", 30, pp.345~361 (1995)
- "William's hematology. 5th ed", pp.1109~ (1995), Baltimore, McGrawl-Hill
- "VMCP", BAP alternating combination chemotherapy is not superior to melphalan prednisolone even in high-risk patients, 1991, 444~448
- "High-dose intravenous melphalan for plasma cell leukemia and myeloma", 2, pp.822~824 (1983)
- "High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma", 70, pp.869~872 (1987)
- "randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma", 335, pp.91~97 (1996)
- "Superiority of tandem autologous transplantation over standard therapy of previously untreated multiple myeloma", 89, pp.789~793 (1997)
- "Single versus double autologous stem-cell transplantation for multiple myeloma", 349, pp.2495~2502 (2003)
- "High dose chemotherapy with autologous stem cell transplantation in multiple myeloma", 34, pp.306~316 (1999)
- "A new staging system for multiple myeloma patients based on the Swothwest Oncology Group SWOG experience", 122, pp.441~450 (2003)
- "Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma", 2, pp.882~885 (1989)
- "Total therapy with tandem transplants for newly diagnosed multiple myeloma", pp.55~65 (1999)
- "Autologous stem cell transplantation after first remission induction treatment in multiple myeloma a report of the French Registry on autologous transplantation in multiple myeloma", 85, pp.3077~3085 (1995)
- "High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma", 12, pp.759~763 (1994)
- "High dose chemotherapy and autologous blood stem cell transplantation in multiple myeloma results of a phase II trial involving 63 patients" (1993)
- "Survival of multiple myeloma patients who are potential candidates for early high dose therapy intensification", autotransplantation and who were conventionally treated, 1996, pp.14, 2167~2173
- "High-dose sequential chemotherapy in multiple myeloma residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting", 85, pp.1596~1602 (1995)
- "Minimal residual disease monitoring in multiple myeloma", 15, pp.197~222 (2002)
- "Role of transplantation in myeloma American Society of Hematology", pp.221~227 (2002), Washington, American Society of Hematology
- "Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy", 13, pp.1116~1119 (2002)
- "Idiotype vaccination of myeloma patients after chemotherapy", 39, pp.807~808 (2000)
- "Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma", 6, pp.621~627 (2000)
- "Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma", 100, pp.755~760 (2002)
- "Chromosome 13 abnormalities identified by FISH analysis and serum 2- microglobulin produce powerful myeloma staging system for patients receving high-dose therapy", 97, pp.1566~1571 (2001)